2nd Peptide Formulation and Delivery Innovation Summit

Peptide bioavailability has been significantly enhanced in recent years, evidenced by Pfizer developing an optimized formulation for its oral GLP-1 drug danuglipron, AbbVie buying out Nimble Therapeutics for its oral peptide assets and J and J advancing development of its IL-23 receptor antagonist peptide to address the high unmet need for a durable oral option. Additionally, innovative excipient and delivery approaches are making oral administration of peptides a clinical reality, but bottlenecks remain.

Returning to Boston as your premier industry-dedicated forum, the 2nd Peptide Formulation and Delivery Innovation Summit addresses how to overcome unique formulation challenges and accelerate innovative delivery technology applications to progress peptide-based therapeutic pipelines towards patients and commercialization.

As peptide-based therapeutics continue to be touted as the Goldilocks drug modality and are set to seriously disrupt the drug development landscape, join this forum to stay ahead of the curve:

Learn about state-of-the-art peptide formulation technologies such as permeation enhancers, nanoparticle encapsulation and structural modification abilities

Overcome technical and scientific challenges in optimizing peptide stability and bioavailability for oral, injectable, inhaled and intra-dermal formulations

Build partnerships with excipient and ingredient providers, device testing services, pre-clinical models and CDMOs that are well-versed in optimizing novel or reformulated peptide drugs, and scaling up manufacturing without compromising drug safety or efficacy

Be part of the industry-dedicated peptide formulation and delivery community that is spearheading innovative peptide formulation and delivery technologies to enhance peptide drug constitution without impacting efficacy, ensure patient adherence and accelerate peptide drug product towards approval.

Speakers: Ankur Sharma Senior Formulation and Development Scientist Hyalo Technologies, Chen Liang Senior Scientist Novo Nordisk, Dhanashree Surve Assistant Scientist University of Miami Miller School of Medicine, Gilles Divita Co-Founder and Chief Executive Officer Divincell / Aanastra, Kinkini Roy Associate Director - Drug Product Development Aviceda Therapeutics, Mi Cai Associate and Registered Patent Attorney Foley Hoag, Mike Davies Founder and Chief Executive Officer Carocell Bio, Mridula Dogra Senior Advisor Eli Lilly, Nitin Joshi Assistant Professor Brigham and Women's Hospital, Harvard Medical School, Patricia Grasso Professor of Medicine, Neuroscience and Experimental Therapeutics Albany Medical College, Peter Knauer Vice President of CMC Xeris Pharmaceuticals, Riet Dams Global Head of Pharmaceutical Product Development and Supply Johnson and Johnson, Rose Kanasty Vice President of Platform Development Lyndra Therapeutics, Ruzica Kolakovic Senior Principal Scientist, Drug Product Development Scientific Integrator Johnson and Johnson, Sinead Bleiel Founder AnaBio Technologies, Siyuan Huang Senior Director - Product Delivery, CMC Project Management Eli Lilly, Stuart Madden Chief Scientific Officer Neurelis, Tarik Soliman Founder and Chief Executive Officer Extend Biosciences, Vincent Jannin Director, R and D and Head of Innovaform™ Accelerator Lonza, Yuhan Lee Co-Founder and Assistant Professor AltrixBio and Harvard Medical School, Zhigao Niu Innovation Lead and Senior Scientist Novo Nordisk